Overview

• Health officials published a list of contractors accused of breaching delivery terms and warned they will be inhabilitated and sanctioned if they do not complete shipments this month.
• Subsecretary Eduardo Clark reported overall supply near full coverage, citing 97% at IMSS and ISSSTE with a lower rate at IMSS‑Bienestar, yet said specific firms remain in noncompliance.
• The government highlighted severe cases including Bioxintegral with 100% non‑delivery and others with high shortfalls, totaling millions of pieces across multiple suppliers.
• Oncology drugs were flagged as the most critical gap, with examples such as Zurich Pharma’s 56,000 pieces not supplied and large pending volumes involving PiSA, Novag Infancia, Amarox Pharma and Zeux Lifesciences.
• Supplier associations ANAPS and Canifarma rejected willful default, arguing the government owes the sector an estimated 14–40 billion pesos and that payments often arrive a year or more after the six‑month contractual term.